CSF ferritin in the clinicopathological progression of Alzheimer’s disease and associations with APOE and inflammation biomarkers
Abstract
A putative role for iron in driving Alzheimer’s disease (AD) progression is complicated by previously reported associations with neuroinflammation, apolipoprotein E and AD proteinopathy. To establish how iron interacts with clinicopathological features of AD and at what disease stage iron influences cognitive outcomes, we investigated the association of cerebrospinal fluid (CSF) biomarkers of iron (ferritin), inflammation (acute phase response proteins) and apolipoproteins with pathological biomarkers (CSF Aβ42/t-tau, p-tau181), clinical staging and longitudinal cognitive deterioration in subjects from the BioFINDER cohort, with replication of key results in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 10, 2022
- Source ID
- 10.1136/jnnp-2022-330052
Entities
People
- Abdel Ali Belaidi
- Anne Roberts
- Ashley Ian Bush
- Blaine Roberts
- Erik Stomrud
- Oskar Hansson
- Pawel Kalinowski
- Scott Ayton
- Sebastian Palmqvist
- Shorena Janelidze
Organizations
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Chiron Corporation
- Cooperative Research Centre
- Eli Lilly and Company
- Foundation for the National Institutes of Health
- GE HealthCare
- Hoffmann-La Roche
- Innogenetics
- Janssen Biotech
- Johnson & Johnson
- Laboratoires Servier
- Medpace
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Health and Medical Research Council
- National Institutes of Health
- Pfizer
- Roche (United States)
- Swedish Research Council
- Takeda Pharmaceutical Company
- United States Department of Defense
- Victoria State Government